Comparison of 208‐week sequential therapy with telbivudine and entecavir in HBeAg‐positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg‐IFNα‐2a therapy: An open‐labelled, randomized, controlled, “real‐life” trial
X. D. Luo; X. F. Chen; Y. Zhou; X. P. Chen
Author Information: Department of Infectious Diseases
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.